The global autoimmune treatment market was valued at $176.6 billion in 2025 and is projected to reach $321.95 billion by 2034, expanding at a 6.9% compound annual growth rate from 2026 to 2034, according to Maximize Market Research. The report covers rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease and other autoimmune disorders, as well as drugs, diagnostic equipment, therapeutic and monitoring equipment, and physical therapy. North America held the largest market share in 2025, while Asia-Pacific is identified as a high-growth region. Adoption of biologics, immunosuppressants, monoclonal antibodies, targeted therapies, biosimilars, precision medicine and biomarker-based treatment is supporting market expansion, although high costs, long-term therapy, reimbursement limitations and uneven specialist access remain constraints. A separate DelveInsight report previously cited in this record estimated the market at approximately $133 billion in 2025 and $255 billion by 2034, highlighting differing market definitions or methodologies.